
    
      This is a placebo-controlled, randomized, double-blind, parallel group, comparative study,
      when patients with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis
      (NASH), are administered elobixibat at 10 mg and cholestyramine powder at 9g( cholestyramine
      4g) once daily for 16 weeks.
    
  